NCT04988074View on ClinicalTrials.gov

Trial of Cemiplimab, or Cemip-Chemo Followed by Biomarker-guided Treatment for Pts w/HPV H&N Ca

PHASE2RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 13, 2021

Primary Completion Date

November 12, 2025

Study Completion Date

August 31, 2026

Conditions
HPV-Related Squamous Cell Carcinoma
Interventions
DRUG

Cemiplimab

Cemiplimab for 9 weeks +/- Carboplatin + Paclitaxel

Trial Locations (1)

21287

RECRUITING

Johns Hopkins University, Baltimore

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER